CATX

SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first meningioma patient was dosed with [212Pb]VMT-α-NET in the Company's ongoing Phase 1/2a study. The new cohort is intended to evaluate the safety, dosimetry, and preliminary anti-tumor activity of lead-based alpha-particle therapy with [212Pb]VMT-α-NET for meningioma (LEMONαDE). The initiation of the meningioma cohort reflects The Company's broader strategy to evaluate [212Pb]VMT-α-NET across somatostatin receptor su

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were consistent with previously disclosed findings at AACR as of March 4, 2026 with continued deepening

SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first patients were dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Phase 1/2a studies in neuroendocrine tumors and solid tumors, respectively. The first patient was treated with [212Pb]VMT-α-NET in a fourth cohort of the Company's ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs)

10-Q - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalabilityThree clinical-stage oncology programs advancing across neuroendocrine tumors, melanoma and FAP-positive solid tumors with multiple clinical catalysts expected in 2026 across VMT-α-NET, VMT01 and PSV359 programs; lead program, VMT-α-NET, advancing toward a registration-enabling studyRegional manufacturing network designed to support reliable supply of ready-to-administer radiopharmaceuticals for clinical development and potential commercialization; Chicago site expected to complete construction in 2026 Cash runway expected into late 2027 to support planned c

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will provide several corporate updates in May 2026. Webcasts of these events, unless noted as press release only, will be posted on the Company's website at www.perspectivetherapeutics.com. Analyst Event on Perspective's Strategy, Enabling Technology, and PipelineAdditional details are available here.Date: May 4, 2026Time: 8:30 a.m. ET First Quarter 2026 Financial Results – Press Release OnlyThe press release will be available on the newsro

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

Updated interim results with an additional ~12 weeks of follow-up since prior update at ASCO-GI in January 2026 and ~25 weeks since ESMO in October 2025Safety update presented on all 64 patients who received at least one treatment and updated efficacy analysis presented on the two patients in Cohort 1 and 23 patients in Cohort 2Objective response in 43% (10 out of 23) of patients in first half of Cohort 2, including an additional new response and confirmation of the initial response reported at ASCO-GI 2026Nine patients experienced deepening of response since the ESMO presentation [212Pb]VMT-α-NET continues to be well-tolerated Initial efficacy data from additional 23 patients in Cohort 2 an

DEFA14A - Perspective Therapeutics, Inc. (0000728387) (Filer)

DEF 14A - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: 25th Annual Needham Virtual Healthcare Conference – Presentation & Fireside ChatDate: Tuesday, April 14, 2026Time: 9:30-10:10 a.m. ET Location: Virtual Piper Sandler Spring Biopharma Symposium – 1x1s onlyDate: Thursday, April 16, 2026Location: Boston, MA About Perspective Therapeutics, Inc.

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place from April 17 to 22, 2026 in San Diego, CA as detailed below. AACR has announced that it will release further details for clinical trial abstracts for the conference on April 17, 2026. PresenterAbstract TitlePresentation DetailsThorvardur Halfdanarson, Mayo Clini

10-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026VMT-α-NET study on track to achieve nearly one year of follow-up in all 46 patients in Cohort 2 by mid-2026; analysis to inform patient selection strategy ongoingData across all dose levels in the VMT-α-NET program provide development optionality and support the build-out of a robust clinical evidence package for submission for presentation to more medical conferences and regulatory engagement in 2026Clinical updates for all three clinical programs are expected to be submitted f

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)